Skip to main content
OpenTrials

Clinical trial condition

Recurrent Renal Cell Carcinoma

Explore clinical trials studying Recurrent Renal Cell Carcinoma. Study availability and eligibility vary by location and protocol.

30 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Recurrent Renal Cell Carcinoma trial results

Completed

Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer

NCT00126503

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +19 more
Locations
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Dana-Farber Harvard Cancer Center Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • University of Pennsylvania/Abramson Cancer Center Philadelphia, Pennsylvania, United States
View Trial Details
Active, Not Recruiting

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

NCT02298959

Conditions
Adenocarcinoma, Adnexal Diseases, Carcinoma, +60 more
Locations
  • Moffitt Cancer Center-International Plaza Tampa, Florida, United States
  • Moffitt Cancer Center - McKinley Campus Tampa, Florida, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
View Trial Details
Active, Not Recruiting

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

NCT02867592

Conditions
Adenocarcinoma, Adrenal Cortex Diseases, Adrenal Cortex Neoplasms, +92 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Kaiser Permanente-Anaheim Anaheim, California, United States
View all 142 locations
View Trial Details
Active, Not Recruiting

Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

NCT03092856

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +17 more
Locations
  • Los Angeles County-USC Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • USC Norris Oncology/Hematology-Newport Beach Newport Beach, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
View Trial Details
Active, Not Recruiting

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

NCT04514484

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Differentiated Thyroid Gland Carcinoma, +141 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • Montefiore Medical Center-Einstein Campus The Bronx, New York, United States
  • University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States
View Trial Details

Related conditions